Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant hypertension – – Lorundrostat 50 mg once daily ...

Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have ...

Baystreet.ca News Commentary – As cancer rates continue to climb worldwide, the race to develop better, faster, and more ...

Baystreet.ca News Commentary – The rising burden of cancer is poised to strain both healthcare systems and patient finances, ...

The shift reflects more than a funding gap - it signals a structural realignment in how cancer breakthroughs may be brought to market. As public systems face pressure and timelines extend, nimble ...

The open benchmark competition will evaluate the ability of AI-powered virtual cell models to generalize to new cell contexts ...

Clinical safety : Data from two human Phase 3 studies in Alzheimer's disease demonstrated a favorable safety profile. “My research and collaboration ... a favorable clinical safety profile. Brief ...

Perfuse Therapeutics is conducting trials for the treatment for glaucoma and diabetic retinopathy, aiming to restore vision ...

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with ...

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The ...